Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial

por Schuind, Anne, Segall, Nathan, Drame, Mamadou, Innis, Bruce L.
Publicado 2015

Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study

por Gillard, Paul, Giet, Didier, Heijmans, Stéphane, Dramé, Mamadou, Walravens, Karl, Roman, François
Publicado 2014

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

por Nagai, Hideaki, Ikematsu, Hideyuki, Tenjinbaru, Kazuyoshi, Maeda, Atsushi, Dramé, Mamadou, Roman, François P
Publicado 2010

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults

por Dagnew, Alemnew F, Vink, Peter, Drame, Mamadou, Willer, David, Salaun, Bruno, Schuind, Anne
Publicado 2020

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

por Leroux-Roels, Isabel, Bernhard, Roger, Gérard, Pascal, Dramé, Mamadou, Hanon, Emmanuel, Leroux-Roels, Geert
Publicado 2008

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview

por Dagnew, Alemnew F., Vink, Peter, Drame, Mamadou, Willer, David O., Salaun, Bruno, Schuind, Anne E.
Publicado 2021

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

por Gillard, Paul, Caplanusi, Adrian, Knuf, Markus, Roman, François, Walravens, Karl, Moris, Philippe, Dramé, Mamadou, Schwarz, Tino F.
Publicado 2012

Characterization of Bacteria on Aerosols From Dust Events in Dakar, Senegal, West Africa

por Marone, Alioune, Kane, Coumba Touré, Mbengue, Malick, Jenkins, Gregory S., Niang, Demba Ndao, Drame, Mamadou Simina, Gernand, Jeremy M.
Publicado 2020

Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age

por Nolan, Terry, Izurieta, Patricia, Lee, Bee-Wah, Chan, Poh Chong, Marshall, Helen, Booy, Robert, Drame, Mamadou, Vaughn, David W.
Publicado 2014

AS03(B)-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial

por Kosalaraksa, Pope, Jeanfreau, Robert, Frenette, Louise, Drame, Mamadou, Madariaga, Miguel, Innis, Bruce L., Godeaux, Olivier, Izurieta, Patricia, Vaughn, David W.
Publicado 2015

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials

por Vaughn, David W, Seifert, Harry, Hepburn, Anne, Dewe, Walthere, Li, Ping, Drame, Mamadou, Cohet, Catherine, Innis, Bruce L, Fries, Louis F
Publicado 2014

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial

por Heijmans, Stéphane, De Meulemeester, Marc, Reynders, Paul, Giet, Didier, Demanet, Etienne, Devresse, Pierre-Yves, Icardi, Giancarlo, Dramé, Mamadou, Roman, François, Gillard, Paul
Publicado 2011

H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

por Moris, Philippe, van der Most, Robbert, Leroux-Roels, Isabel, Clement, Frédéric, Dramé, Mamadou, Hanon, Emmanuel, Leroux-Roels, Geert G., Van Mechelen, Marcelle
Publicado 2010

Observed and Modeled Seasonal Air Quality and Respiratory Health in Senegal During 2015 and 2016

por Toure, Nafissatou Oumar, Gueye, Ndeye Ramatoulaye Diagne, Mbow‐Diokhane, Aminata, Jenkins, Gregory S., Li, Maggie, Drame, Mamadou S., Coker, Karen Adjoa Ronke, Thiam, Khady
Publicado 2019

Long-term booster schedules with AS03(A)-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults

por Gillard, Paul, Chu, Daniel Wai Sing, Hwang, Shinn-Jang, Yang, Pan-Chyr, Thongcharoen, Prasert, Lim, Fong Seng, Dramé, Mamadou, Walravens, Karl, Roman, François
Publicado 2014

Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging St...

por Kim, Joon Hyung, Drame, Mamadou, Puthanakit, Thanyawee, Chiu, Nan-Chang, Supparatpinyo, Khuanchai, Huang, Li-Min, Chiu, Cheng-Hsun, Chen, Po-Yen, Hwang, Kao-Pin, Danier, Jasur, Friel, Damien, Salaun, Bruno, Woo, Wayne, Vaughn, David W., Innis, Bruce, Schuind, Anne
Publicado 2021

Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children...

por Claeys, Carine, Drame, Mamadou, García-Sicilia, José, Zaman, Khalequ, Carmona, Alfonso, Tran, Phu My, Miranda, Mariano, Martinón-Torres, Federico, Thollot, Franck, Horn, Michael, Schwarz, Tino F., Behre, Ulrich, Merino, José M., Sadowska-Krawczenko, Iwona, Szymański, Henryk, Schu, Peter, Neumeier, Elisabeth, Li, Ping, Jain, Varsha K., Innis, Bruce L.
Publicado 2018